GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Cyclically Adjusted PB Ratio

Cytokinetics (FRA:KK3A) Cyclically Adjusted PB Ratio : 49.33 (As of May. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Cytokinetics's current share price is €44.40. Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.90. Cytokinetics's Cyclically Adjusted PB Ratio for today is 49.33.

The historical rank and industry rank for Cytokinetics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:KK3A' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.3   Med: 2.41   Max: 82.95
Current: 49.54

During the past years, Cytokinetics's highest Cyclically Adjusted PB Ratio was 82.95. The lowest was 0.30. And the median was 2.41.

FRA:KK3A's Cyclically Adjusted PB Ratio is ranked worse than
98.93% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs FRA:KK3A: 49.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cytokinetics's adjusted book value per share data for the three months ended in Mar. 2024 was €-3.479. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.90 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cytokinetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Cyclically Adjusted PB Ratio Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 9.38 23.38 27.44 74.02

Cytokinetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.55 22.79 22.91 74.02 71.90

Competitive Comparison of Cytokinetics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PB Ratio falls into.



Cytokinetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cytokinetics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=44.40/0.9
=49.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cytokinetics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.479/131.7762*131.7762
=-3.479

Current CPI (Mar. 2024) = 131.7762.

Cytokinetics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.582 100.560 2.073
201409 1.561 100.428 2.048
201412 1.931 99.070 2.568
201503 2.008 99.621 2.656
201506 1.722 100.684 2.254
201509 1.547 100.392 2.031
201512 1.591 99.792 2.101
201603 1.313 100.470 1.722
201606 1.093 101.688 1.416
201609 1.831 101.861 2.369
201612 2.201 101.863 2.847
201703 2.054 102.862 2.631
201706 2.914 103.349 3.716
201709 2.290 104.136 2.898
201712 1.720 104.011 2.179
201803 1.496 105.290 1.872
201806 1.178 106.317 1.460
201809 0.817 106.507 1.011
201812 0.417 105.998 0.518
201903 0.054 107.251 0.066
201906 -0.075 108.070 -0.091
201909 -0.305 108.329 -0.371
201912 -0.166 108.420 -0.202
202003 -0.696 108.902 -0.842
202006 -1.157 108.767 -1.402
202009 1.799 109.815 2.159
202012 1.312 109.897 1.573
202103 0.796 111.754 0.939
202106 0.190 114.631 0.218
202109 2.525 115.734 2.875
202112 2.545 117.630 2.851
202203 1.234 121.301 1.341
202206 1.227 125.017 1.293
202209 -0.171 125.227 -0.180
202212 -1.074 125.222 -1.130
202303 -2.237 127.348 -2.315
202306 -3.205 128.729 -3.281
202309 -4.272 129.860 -4.335
202312 -3.485 129.419 -3.548
202403 -3.479 131.776 -3.479

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cytokinetics  (FRA:KK3A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cytokinetics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (FRA:KK3A) Business Description

Industry
Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines